CRVS
Corvus Pharmaceuticals, Inc.Healthcare$14.69
▲ Bullish
Mkt Cap: $1.23B|Float: 72.2M|SI: 22.2%|DTC: 13.4
Data as of market close Apr 2, 2026
IV Rank
93
IV Pctl
78%
HV 20d
68.7%
52W Range
$3-$27
ATR(14)
$0.95
Exp. Move
±12.9%
P/C Ratio
0.27
Earnings
May 7
GEX Positive
DEX Long
Net Call Premium
IV High
Max Pain Below
Exp. Move Wide
Low Put/Call
CRVS Key Options Data
- IV Rank
- 92.6%
- Total GEX
- $0.00B
- Total DEX
- $1.2M
- Max Pain
- $10.00
- Expected Move
- ±12.9%
- Put/Call OI
- 0.27
- Net Premium
- $0.4M
- Spot Price
- $14.69
Gamma Exposure (GEX)
Delta Exposure (DEX)
Expected Move by Expiration
| Expiration | DTE | Expected Move | Move % | Lower | Upper |
|---|---|---|---|---|---|
| 2026-04-17 | 15 | ±$1.90 | ±12.9% | $12.79 | $16.59 |
| 2026-05-15 | 43 | ±$3.52 | ±24.0% | $11.16 | $18.21 |
| 2026-06-18 | 77 | ±$4.50 | ±30.6% | $10.19 | $19.19 |
| 2026-07-17 | 106 | ±$5.25 | ±35.7% | $9.44 | $19.94 |
| 2026-10-16 | 197 | ±$3.60 | ±24.5% | $11.09 | $18.29 |
| 2027-01-15 | 288 | ±$8.75 | ±59.6% | $5.94 | $23.44 |
Explore CRVS options data including implied volatility rankings, gamma and delta exposure, max pain levels, and expected price moves. AI-generated reports provide directional, income, and earnings analysis.